By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Paced by growth in its Analytical Technologies segment, Thermo Fisher Scientific today reported 3 percent revenue growth year over year in the first quarter.

For the three months ended April 2, the company posted revenues of $2.72 billion, up from $2.63 billion a year ago, and surpassing analyst forecasts for $2.65 billion. Acquisitions added 2 percentage points to revenues, while currency translation added 1 percentage point.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.